EFTR

0.00020.00%
NR

Neal Rosen

Member of Clinical & Scientific Advisory Board

Dr. Neal Rosen, Ph.D., M.D., serves as a Member in the Department of Medicine and in the Molecular Pharmacology and Chemistry Program at Memorial Sloan-Kettering Cancer Center, where he is also the Director of the Center for Mechanism-Based Therapeutics. He holds the Enid A. Haupt Chair in Medical Oncology and is a Professor of Pharmacology, Cell Biology and Medicine at Cornell University Medical School. He serves as a Member of the Scientific Advisory Board of Kadmon Holdings, Inc., TetraLogic Pharmaceuticals Corporation, BeOne Medicines AG since 2025, Kura Oncology, Inc. (as Scientific Advisor), Conforma Therapeutics Corporation, Acretia, Inc., NexGenix Pharmaceuticals Holdings, Inc., Intellikine LLC, Tarveda Therapeutics, Inc., eFFECTOR Therapeutics, Inc., Ribon Therapeutics, Inc. since December 2019, Fidelity Biosciences, Concarlo Holdings, LLC, and Felicitex Therapeutics Inc. Previously, Dr. Rosen served on the Scientific Advisory Boards of BeOne Medicines AG from April 2021, Amphora Discovery Corporation, AngioGenex, Inc., Mitra Biotech Pvt Ltd., Zai Lab Limited from 2016 to October 2024, Ikena Oncology, Inc., and as a Scientific Consultant of NexGenix Pharmaceuticals Holdings, Inc. He was a Senior Investigator of the National Cancer Institute and an Associate Professor of Medicine at the Lombardi Cancer Center at Georgetown University. Dr. Rosen is world-renowned for his research involving signal transduction pathways in cancer cells, with major interests in the identification of key molecular events and the use of this information for developing mechanism-based therapeutic strategies. He has played an important role in the development of multiple inhibitors of receptor mediated signal transduction and established the concept that the Hsp90 protein chaperone is a therapeutic target. He was the recipient of the NIH/NCI Outstanding Investigator Award in 2016. Dr. Rosen obtained a B.S. in Chemistry from Columbia College Chicago; and an M.D. and a Ph.D. in Molecular Biology from the Albert Einstein College of Medicine. He completed a residency in Internal Medicine at the Brigham and Women’s Hospital and post-doctoral training and a fellowship in Medical Oncology at the National Cancer Institute.

Positions